Advertisement

Meeting Coverage

Masitinib Possible New Treatment of Progressive MS

Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...

Read More

Management of PPMS and SPMS with approved DMT

In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....

Read More
Advertisement